Tapentadol Versus Tramadol Analgesia Post Cardiac Surgery (vasso-annie)
Primary Purpose
Postoperative Pain, Surgery, Pain, Postoperative
Status
Recruiting
Phase
Not Applicable
Locations
Greece
Study Type
Interventional
Intervention
Group tapentadol 50 mg
group tapentadol 75 mg
group tramadol 100 mg
Sponsored by
About this trial
This is an interventional prevention trial for Postoperative Pain focused on measuring tapentadol, tramadol
Eligibility Criteria
Inclusion Criteria:
- age <75 years old
- patients discharged from Intensive Care Unit (ICU) in less than 30 hours
- elective cardiac surgery
Exclusion Criteria:
- hepatic failure (increased transaminase levels
- renal failure (creatinine> 2 mg/dL)
- ileus
- emergency surgery (hemorrhage, tamponade, aortic dissection)
- readmission in ICU
- treatment with monoaminoxidase inhibitors, selective serotonine reuptake inhibitors or antiepileptics
- age>75 years old
- communication or language barriers
- Lack of informed consent
Sites / Locations
- Onassis Cardiac Surgery CentreRecruiting
- Ygeia General Hospital of AthensRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Active Comparator
Active Comparator
Active Comparator
Arm Label
tapentadol 50 mg
tapentadol 75 mg
tramadol 100 mg
Arm Description
tapentadol 50mg p.o 3 times daily for two days
tapentadol 75 mg p.o 3 times daily for two days
tramadol 100 mg p.o 3 times daily for two days
Outcomes
Primary Outcome Measures
change from baseline in pain score at rest
pain score will be assessed by the use of Numeric Rating Scale (NRS) 2 hours after analgesia administration, ranging from 0 to 10, where 0 means "no pain" and 10 means "worst pain imaginable"
change from baseline in pain score during coughing
pain score will be assessed by the use of Numeric Rating Scale (NRS) 2 hours after analgesia administration, ranging from 0 to 10, where 0 means "no pain" and 10 means "worst pain imaginable"
side effects
side effects resulting from analgesic administration, yes or no
incidence of chronic pain 3 months after surgery
occurrence of chronic pain at the site of the operation 3 months after surgery, with the use of the Brief Pain Inventory Questionnaire
incidence of chronic pain 6 months after surgery
occurrence of chronic pain at the site of the operation 6 months after surgery, with the use of the Brief Pain Inventory Questionnaire
incidence of neuropathic pain 3 months after surgery
occurrence of neuropathic pain 3 months after surgery, with the use of the Douleur Neuropathique (DN4) Questionnaire
incidence of neuropathic pain 6 months after surgery
occurrence of neuropathic pain 6 months after surgery, with the use of the Douleur Neuropathique (DN4) Questionnaire
Secondary Outcome Measures
hospitalization time
duration of hospital stay after surgery in days
satisfaction from postoperative analgesia
satisfaction from postoperative analgesia on a six-point Likert scale with 1 marked as minimal satisfaction and 6 as maximal satisfaction
Full Information
NCT ID
NCT04718116
First Posted
January 17, 2021
Last Updated
February 5, 2023
Sponsor
Aretaieion University Hospital
1. Study Identification
Unique Protocol Identification Number
NCT04718116
Brief Title
Tapentadol Versus Tramadol Analgesia Post Cardiac Surgery
Acronym
vasso-annie
Official Title
Management of Postsurgical Pain After Cardiac Operations: Comparison of Tapentadol and Tramadol Analgesia
Study Type
Interventional
2. Study Status
Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
November 1, 2022 (Actual)
Primary Completion Date
December 31, 2024 (Anticipated)
Study Completion Date
December 31, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Aretaieion University Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The aim of this randomized one-blinded study will be to evaluate the efficacy and tolerability of two different oral doses of tapentadol and compare it to tramadol (an opioid commonly used to treat post-surgical pain) in cardiac surgery patients
Detailed Description
Management of post-surgical pain is a daily challenge for every anaesthetist. Undertreated post-surgical pain can result in cardiovascular, pulmonary and gastrointestinal complications, as well as chronic pain and negative psychological effects. A negative impact may be seen on immune function, coagulation and wound healing. Opioids have been the cornerstone in the treatment of pain after cardiac surgery. However, opioids have a number of adverse effects such as respiratory depression, gastrointestinal alterations, dizziness, delirium, addiction.
Tapentadol is a new synthetic opioid with dual mechanism of action. It acts as a mu-receptor agonist, as well as norepinephrine reuptake inhibitor. It is used to treat moderate to severe pain and is associated with fewer adverse effects compared to other opioids.
The aim of this randomized one-blinded study will be to evaluate the efficacy and tolerability of two different oral doses of tapentadol and compare it to tramadol (an opioid commonly used to treat post-surgical pain).
Patients undergoing cardiac surgery and being discharged from ICU to ward within 30 hours of surgery, will be divided into 3 groups. Group A will receive tapentadol 50mg p.o 3 times daily for two days, group B will receive tapentadol 75 mg p.o 3 times daily for two days and group C will receive tramadol 100 mg p.o 3 times daily for two days. Pain level will be assessed with Numeric Rating Scale (NRS), before drug administration and two hours after drug administration. Overall patient satisfaction will be assessed with Likert scale. Brief Pain Inventory( short form) and DN4 questionnaire will be used to detect chronic pain and neuropathic pain respectively, 3 and 6 months after surgery.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Postoperative Pain, Surgery, Pain, Postoperative, Pain, Acute, Pain, Chronic, Pain, Procedural, Pain, Neuropathic, Analgesia
Keywords
tapentadol, tramadol
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
90 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
tapentadol 50 mg
Arm Type
Active Comparator
Arm Description
tapentadol 50mg p.o 3 times daily for two days
Arm Title
tapentadol 75 mg
Arm Type
Active Comparator
Arm Description
tapentadol 75 mg p.o 3 times daily for two days
Arm Title
tramadol 100 mg
Arm Type
Active Comparator
Arm Description
tramadol 100 mg p.o 3 times daily for two days
Intervention Type
Drug
Intervention Name(s)
Group tapentadol 50 mg
Other Intervention Name(s)
group A
Intervention Description
patients in group A will receive tapentadol 50 mg p.o 3 times daily for two days
Intervention Type
Drug
Intervention Name(s)
group tapentadol 75 mg
Other Intervention Name(s)
group B
Intervention Description
patients in group B will receive tapentadol 75 mg p.o 3 times daily for two days
Intervention Type
Drug
Intervention Name(s)
group tramadol 100 mg
Other Intervention Name(s)
group C
Intervention Description
patients in group C will receive tramadol 100 mg p.o 3 times daily for two days
Primary Outcome Measure Information:
Title
change from baseline in pain score at rest
Description
pain score will be assessed by the use of Numeric Rating Scale (NRS) 2 hours after analgesia administration, ranging from 0 to 10, where 0 means "no pain" and 10 means "worst pain imaginable"
Time Frame
2 hours after analgesia administration
Title
change from baseline in pain score during coughing
Description
pain score will be assessed by the use of Numeric Rating Scale (NRS) 2 hours after analgesia administration, ranging from 0 to 10, where 0 means "no pain" and 10 means "worst pain imaginable"
Time Frame
2 hours after analgesia administration
Title
side effects
Description
side effects resulting from analgesic administration, yes or no
Time Frame
2 hours after analgesia administration
Title
incidence of chronic pain 3 months after surgery
Description
occurrence of chronic pain at the site of the operation 3 months after surgery, with the use of the Brief Pain Inventory Questionnaire
Time Frame
3 months after surgery
Title
incidence of chronic pain 6 months after surgery
Description
occurrence of chronic pain at the site of the operation 6 months after surgery, with the use of the Brief Pain Inventory Questionnaire
Time Frame
6 months after surgery
Title
incidence of neuropathic pain 3 months after surgery
Description
occurrence of neuropathic pain 3 months after surgery, with the use of the Douleur Neuropathique (DN4) Questionnaire
Time Frame
3 months after surgery
Title
incidence of neuropathic pain 6 months after surgery
Description
occurrence of neuropathic pain 6 months after surgery, with the use of the Douleur Neuropathique (DN4) Questionnaire
Time Frame
6 months after surgery
Secondary Outcome Measure Information:
Title
hospitalization time
Description
duration of hospital stay after surgery in days
Time Frame
postoperatively, an average period of 10 days
Title
satisfaction from postoperative analgesia
Description
satisfaction from postoperative analgesia on a six-point Likert scale with 1 marked as minimal satisfaction and 6 as maximal satisfaction
Time Frame
72 hours postoperatively
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
age <75 years old
patients discharged from Intensive Care Unit (ICU) in less than 30 hours
elective cardiac surgery
Exclusion Criteria:
hepatic failure (increased transaminase levels
renal failure (creatinine> 2 mg/dL)
ileus
emergency surgery (hemorrhage, tamponade, aortic dissection)
readmission in ICU
treatment with monoaminoxidase inhibitors, selective serotonine reuptake inhibitors or antiepileptics
age>75 years old
communication or language barriers
Lack of informed consent
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Kassiani Theodoraki, PhD, DESA
Phone
+306974634162
Email
ktheodoraki@hotmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kassiani Theodoraki, PhD, DESA
Organizational Affiliation
Aretaieion University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Onassis Cardiac Surgery Centre
City
Athens
ZIP/Postal Code
17674
Country
Greece
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Theophani Antoniou, MD, PhD
Email
antoniou_fani@yahoo.gr
First Name & Middle Initial & Last Name & Degree
Vassiliki Lavranou, MD
Email
vasolav82@hotmail.gr
Facility Name
Ygeia General Hospital of Athens
City
Athens
Country
Greece
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Vassiliki Lavranou, MD
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
24319854
Citation
Raksamani K, Wongkornrat W, Siriboon P, Pantisawat N. Pain management after cardiac surgery: are we underestimating post sternotomy pain? J Med Assoc Thai. 2013 Jul;96(7):824-8.
Results Reference
background
PubMed Identifier
16677435
Citation
Roediger L, Larbuisson R, Lamy M. New approaches and old controversies to postoperative pain control following cardiac surgery. Eur J Anaesthesiol. 2006 Jul;23(7):539-50. doi: 10.1017/S0265021506000548.
Results Reference
background
PubMed Identifier
16733157
Citation
Taillefer MC, Carrier M, Belisle S, Levesque S, Lanctot H, Boisvert AM, Choiniere M. Prevalence, characteristics, and predictors of chronic nonanginal postoperative pain after a cardiac operation: a cross-sectional study. J Thorac Cardiovasc Surg. 2006 Jun;131(6):1274-80. doi: 10.1016/j.jtcvs.2006.02.001.
Results Reference
background
PubMed Identifier
19681771
Citation
Gjeilo KH, Klepstad P, Wahba A, Lydersen S, Stenseth R. Chronic pain after cardiac surgery: a prospective study. Acta Anaesthesiol Scand. 2010 Jan;54(1):70-8. doi: 10.1111/j.1399-6576.2009.02097.x. Epub 2009 Aug 13.
Results Reference
background
PubMed Identifier
30333328
Citation
Nachiyunde B, Lam L. The efficacy of different modes of analgesia in postoperative pain management and early mobilization in postoperative cardiac surgical patients: A systematic review. Ann Card Anaesth. 2018 Oct-Dec;21(4):363-370. doi: 10.4103/aca.ACA_186_17.
Results Reference
background
PubMed Identifier
24578192
Citation
Tzschentke TM, Christoph T, Kogel BY. The mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadol. CNS Drugs. 2014 Apr;28(4):319-29. doi: 10.1007/s40263-014-0151-9.
Results Reference
background
PubMed Identifier
27867511
Citation
Langford RM, Knaggs R, Farquhar-Smith P, Dickenson AH. Is tapentadol different from classical opioids? A review of the evidence. Br J Pain. 2016 Nov;10(4):217-221. doi: 10.1177/2049463716657363. Epub 2016 Jul 25.
Results Reference
background
PubMed Identifier
22698264
Citation
Raffa RB, Buschmann H, Christoph T, Eichenbaum G, Englberger W, Flores CM, Hertrampf T, Kogel B, Schiene K, Strassburger W, Terlinden R, Tzschentke TM. Mechanistic and functional differentiation of tapentadol and tramadol. Expert Opin Pharmacother. 2012 Jul;13(10):1437-49. doi: 10.1517/14656566.2012.696097. Epub 2012 Jun 15.
Results Reference
background
PubMed Identifier
25133962
Citation
Lee YK, Ko JS, Rhim HY, Lee EJ, Karcher K, Li H, Shapiro D, Lee HS. Acute postoperative pain relief with immediate-release tapentadol: randomized, double-blind, placebo-controlled study conducted in South Korea. Curr Med Res Opin. 2014 Dec;30(12):2561-70. doi: 10.1185/03007995.2014.954665. Epub 2014 Aug 27.
Results Reference
background
Learn more about this trial
Tapentadol Versus Tramadol Analgesia Post Cardiac Surgery
We'll reach out to this number within 24 hrs